QCM
CORT icon

QRG Capital Management’s Corcept Therapeutics CORT Stock Holding History

QRG Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$786K Buy
9,042
+1,834
+25% +$111K 0.01% 715
2026
Q1 		$291K Sell
7,208
-956
-12% -$35.7K ﹤0.01% 967
2025
Q4 		$284K Buy
8,164
+353
+5% +$27.7K ﹤0.01% 937
2025
Q3 		$649K Sell
7,811
-102,941
-93% -$7.45M 0.01% 635
2025
Q2 		$8.13M Buy
110,752
+13,829
+14% +$1M 0.07% 237
2025
Q1 		$11.1M Buy
96,923
+558
+0.6% +$34K 0.11% 181
2024
Q4 		$4.86M Buy
96,365
+6,163
+7% +$323K 0.05% 293
2024
Q3 		$4.17M Buy
90,202
+6,691
+8% +$238K 0.05% 314
2024
Q2 		$2.71M Buy
83,511
+8,891
+12% +$244K 0.03% 362
2024
Q1 		$1.88M Sell
74,620
-4,643
-6% -$110K 0.02% 431
2023
Q4 		$2.57M Buy
79,263
+7,325
+10% +$201K 0.04% 361
2023
Q3 		$1.96M Buy
+71,938
New +$2.08M 0.03% 374

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QRG Capital Management's CORT Position: Q2 2026 in Review

QRG Capital Management increased its Corcept Therapeutics (CORT) stake by 25% in Q2 2026, buying an estimated $111K and bringing the position to 9,042 shares worth $786K. The position accounts for 0.01% of the portfolio, ranked #715.

QRG Capital Management first reported a position in CORT in Q3 2023 and has held it in 12 quarters since. The position peaked at $11.1M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • QRG Capital Management held 9,042 shares of Corcept Therapeutics worth $786K as of Q2 2026.
  • QRG Capital Management bought 1,834 Corcept Therapeutics shares in Q2 2026, an estimated $111K.
  • Corcept Therapeutics made up 0.01% of QRG Capital Management's portfolio in Q2 2026, its #715 holding.
  • QRG Capital Management first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • QRG Capital Management's Corcept Therapeutics position peaked at $11.1M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.